Sage Journals: Discover world-class research

Abstract

Keywords

neonates term infants preterm infants policy policy reform drug development

Get full access to this article

View all access options for this article.

References

US Food and Drug Administration Modernization Act of 1997. 105th Congress, PL 105-115, 21 USC 301 (1997); 2007 (Feb 21). https://www.gpo.gov/fdsys/pkg/PLAW-105publ115/pdf/PLAW-105publ115.pdf. Accessed July 25, 2018.

Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients—FDA. Final rule. Fed Regist. 1998;63(231):66631–66672. https://wayback.archive-it.org/7993/20170405140724/https://www.fda.gov/ohrms/dockets/ac/03/briefing/3927B1_05_1998%20Pediatric%20Rule.htm. Accessed July 25, 2018.

Arshagouni

Federal Court invalidates the FDA pediatric rule: AAPS v. FDA. 2002. https://www.law.uh.edu/healthlaw/perspectives/Children/021223Federal.html. Accessed July 25, 2018.

Best Pharmaceuticals for Children Act, 21 USC 301 (2002); 21 USC 301 (Pub L No. 107-109). http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=107_cong_public_laws&docid=f:publ109.107. Accessed July 25, 2018.

US Food and Drug Administration Safety and Innovation Act. PL 112-144. 2012 (112–144). http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed July 25, 2018.

Pediatric Research Equity Act of 2003. Pub L No. 108-155 (2003). http://www.gpo.gov/fdsys/pkg/PLAW-108publ155/pdf/PLAW-108publ155.pdf. Accessed July 25, 2018.

Biologics Price Competition and Innovation Act in The Patient Protection and Affordable Care Act, 111-148 (2010). https://www.gpo.gov/fdsys/pkg/PLAW-111publ148/html/PLAW-111publ148.htm. Accessed July 25, 2018.

New pediatric labeling information database. 2018. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed July 25, 2018.

Bucci-Rechtweg

. Enhancing the pediatric drug development framework to deliver better pediatric therapies tomorrow. Clin Ther. 2017;39:1920–1932.

10.

Sachs

Avant

Lee

Rodriguez

Murphy

. Pediatric information in drug product labeling. JAMA. 2012;307:1914–1915.

11.

Laughon

Avant

Tripathi

et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168:130–136.

12.

Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Safe and Effective Medicines For Children. Washington, DC: National Academies Press Institute of Medicine; 2013.

13.

Stiers

Ward

. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 2014;168:106–108.

14.

Ward

Benjamin

Jr Barrett

et al.

Considerations regarding safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Ped Res. 2017;81:692–711.

15.

Ward

Sherwin

. Ethics of drug studies in the newborn. Paediatr Drugs. 2015;17:37–42.

16.

Schmidt

Roberts

Davis

et al. Prediction of late death or disability at age 5 years using a count of 3 neonatal morbidities in very low birth weight infants. J Pediatr 167:982-986e982.

17.

March of Dimes. The impact of premature birth on society. 2015. https://www.marchofdimes.org/mission/the-economic-and-societal-costs.aspx. Accessed July 25, 2018.

18.

Harrison

Goodman

. Epidemiologic trends in neonatal intensive care, 2007-2012. JAMA Pediatr. 2015;169:855–862.

Tiny and Forgotten: A Call for Focused Neonatal Policy Reform

Abstract

Keywords

Get full access to this article

References